New Era of Weight-Loss Pills Is Here
A new era of weight-loss pills has arrived, after the Food and Drug Administration (FDA) approved a daily pill version of Novo Nordisk’s drug Wegovy
TL;DR
- The FDA has approved a daily pill version of Novo Nordisk's weight-loss drug Wegovy, which contains semaglutide.
- The new pill offers an alternative for patients who prefer not to use injectable medications.
- The starting price for the Wegovy pill will be $149, following an agreement with President Trump.
- Novo Nordisk is also testing semaglutide for children and exploring its use for addiction, neurological conditions, and anti-aging.
- Significant revenue was generated by semaglutide drugs for Novo Nordisk in 2023, making it Europe's most valuable company.
- Reports of psychiatric issues, hormonal problems, stomach contents inhalation, and permanent diarrhea have been linked to these drugs.
- Tens of thousands of lawsuits have been filed against Novo Nordisk and Eli Lilly for alleged physical damages.